US FDA delay of postsurgery pain drug cuts like a knife for Pacira
This article was originally published in Scrip
Executive Summary
Investors reacted to Pacira Pharmaceuticals' revelation on 14 June that the US FDA delayed by three months its decision on the new drug application (NDA) for the company's investigational long-acting non-opioid postsurgical analgesic Exparel (bupivacaine extended-release liposome injection) by pushing shares of the firm down as low as 18.3%, or $2.42.